Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1962 1
1963 2
1964 3
1966 3
1968 6
1969 1
1970 6
1971 8
1972 5
1973 7
1974 9
1975 5
1976 6
1977 2
1978 7
1979 8
1980 10
1981 11
1982 13
1983 14
1984 10
1985 15
1986 17
1987 21
1988 16
1989 20
1990 19
1991 21
1992 21
1993 17
1994 14
1995 13
1996 9
1997 25
1998 28
1999 21
2000 36
2001 39
2002 37
2003 39
2004 35
2005 35
2006 37
2007 19
2008 28
2009 25
2010 38
2011 39
2012 54
2013 50
2014 59
2015 55
2016 63
2017 69
2018 80
2019 93
2020 103
2021 110
2022 128
2023 108
2024 67

Text availability

Article attribute

Article type

Publication date

Search Results

1,658 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Kumada T. Hatanaka T, et al. Among authors: tada t. Aliment Pharmacol Ther. 2024 Oct 4. doi: 10.1111/apt.18319. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39367644 No abstract available.
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. Rossari F, et al. Among authors: tada t. Liver Cancer. 2024 Apr 10;13(5):522-536. doi: 10.1159/000537915. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39296620 Free PMC article.
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hatanaka T, et al. Among authors: tada t. Aliment Pharmacol Ther. 2024 Sep 4. doi: 10.1111/apt.18237. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39233317
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Tada T, Kurosaki M, Toyoda H, Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N. Tada T, et al. Liver Int. 2024 Sep 2. doi: 10.1111/liv.16093. Online ahead of print. Liver Int. 2024. PMID: 39223936
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, Ishikawa T, Abe H, Kato K, Morishita A, Tani J, Okubo T, Nagao M, Iwabu M, Iwakiri K. Arai T, et al. Among authors: tada t. Diabetes Obes Metab. 2024 Nov;26(11):4958-4965. doi: 10.1111/dom.15898. Epub 2024 Sep 2. Diabetes Obes Metab. 2024. PMID: 39223865
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Rimini M, Montes M, Amadeo E, Vitiello F, Kudo M, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Salani F, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Camera S, Rossari F, Foti S, Kumada T, Hiraoka A, Iwamoto H, Rizzato MD, Himmelsbach V, Masi G, Corradi M, Celsa C, Fabio C, Frassineti GL, Cascinu S, Casadei-Gardini A, Presa J. Rimini M, et al. Among authors: tada t. Sci Rep. 2024 Aug 30;14(1):20200. doi: 10.1038/s41598-024-70928-z. Sci Rep. 2024. PMID: 39215078 Free PMC article.
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Mori N, Tamaki N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Mori N, et al. Among authors: tada t. Invest New Drugs. 2024 Aug 30. doi: 10.1007/s10637-024-01470-y. Online ahead of print. Invest New Drugs. 2024. PMID: 39212893
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Tamaki N, et al. Among authors: tada t. Anticancer Res. 2024 Sep;44(9):3913-3918. doi: 10.21873/anticanres.17219. Anticancer Res. 2024. PMID: 39197893
1,658 results